Literature DB >> 9219386

Society for Research on Nicotine and Tobacco.

S J Heishman1, D J Balfour, N L Benowitz, D K Hatsukami, J M Lindstrom, J K Ockene.   

Abstract

The proceedings of the second annual scientific conference of the Society for Research on Nicotine and Tobacco are summarized. The goal of the annual conference was to disseminate information about ongoing nicotine research from biological, behavioral and social perspectives. Data were presented describing our current understanding of the structure and function of neuronal nicotinic acetylcholine receptors, by which nicotine exerts most, if not all, of its effects in the brain. The conformational complexity of receptor subunits expressed in different brain areas contributes significantly to the complexity of responses observed to nicotinic agonists. Nicotine is being developed as a medication that might be used to maintain smoking cessation and to treat various medical diseases. The potential toxicity of nicotine, apart from cigarette smoking, is an important variable in assessing the benefits and risks of such therapeutic applications. The risks of nicotine-containing medications appear to be far less than those associated with tobacco use. Recent data indicate that cigarette smoking is increasing among young in the United States. Adolescent smokers are interested in quitting and make frequent quit attempts, but are usually not successful. Effective methods are needed to manage adolescent smokers before they become heavily addicted. Nicotine replacement as a pharmacological treatment for smoking cessation has made a significant contribution in improving quit rates. New medications have been developed that target specific populations of smokers.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9219386

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  1 in total

1.  Permissive nicotine regulation as a complement to traditional tobacco control.

Authors:  Walton Sumner
Journal:  BMC Public Health       Date:  2005-02-24       Impact factor: 3.295

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.